Cassava Sciences CMO retiring; new COO/Legal and SVP Clinical Dev appointed

FILANA THERAPEUTICS, INC.

CMO Dr. James Kupiec retiring effective May 9, 2025.
R. Christopher Cook promoted to COO & Legal Officer from SVP/GC; base salary raised to $475,000.
Dr. Jack Moore appointed SVP Clinical Development effective April 28, 2025.
CFO Eric Schoen's employment agreement amended and restated; base salary unchanged.
Company advancing simufilam for TSC-related epilepsy after Alzheimer's program.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

R. Christopher Cook

Chief Operating and Legal Officer

FLNA · FILANA THERAPEUTICS, INC.

Effective: 2025-04-18
Filed: April 21, 2025, 7:59 PM ET

On April 18, 2025, Mr. Cook, previously our Senior Vice President and General Counsel, was appointed Chief Operating and Legal Officer of the Company.

Departed

James W. Kupiec

Chief Medical Officer

FLNA · FILANA THERAPEUTICS, INC.

Effective: 2025-05-09
Filed: April 21, 2025, 7:59 PM ET

On April 15, 2025, James W. Kupiec, M.D. informed Cassava Sciences, Inc. (the “Company”) of his intent to retire and tendered his resignation as the Company’s Chief Medical Officer, effective as of May 9, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Christopher Cook was appointed as Chief Operating and Legal Officer at FILANA THERAPEUTICS, INC..

Action: appointed
Role: Chief Operating and Legal Officer

Exact text from the filing

On April 18, 2025, Mr. Cook, previously our Senior Vice President and General Counsel, was appointed Chief Operating and Legal Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James W. Kupiec resigned as Chief Medical Officer at FILANA THERAPEUTICS, INC..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On April 15, 2025, James W. Kupiec, M.D. informed Cassava Sciences, Inc. (the “Company”) of his intent to retire and tendered his resignation as the Company’s Chief Medical Officer, effective as of May 9, 2025.

View on SEC.gov

FILANA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-25-012540

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.